On Jan. 5, 2021, AIM ImmunoTech announced that the active AMP-511 Expanded Access Program (EAP) had dosed its first COVID-19 ﾓLong Haulerﾔ patient with the drug Ampligen (rintatolimod), marking a significant milestone in AIMﾒs efforts to develop an effective therapeutic for people suffering from post-COVID-19 infection chronic fatigue-like symptoms.

The EAP was conducted at Hunter-Hopkins Center in Charlotte, N.C., and at Sierra Internal Medicine in Incline Village, Nevada.